Cortexin in a longitudinal study of severe atypical autism
N. V. Simashkova, L. P. Yakupova · 2008 · Autism and Developmental Disorders. 2008;6(1):1–22.
Reported findings and study design
No measured outcomes in the accessed disclosure
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Cortexin-specific clinical outcomes | The study did not report outcomes or an exposure count for Cortexin separately from the wider care program. |
Source for these results ↗ · Reviewed 2026-11-10
For research and education. Consult a qualified clinician for medical advice.
Study limitations and source details
Study limitations
- The 80 cases are a subset of the initial 370. Neither count represents a verified Cortexin-exposed group.
- Concurrent medications and psychosocial care prevent attribution of changes to Cortexin.
Related publications may cover the same research program or participants.
Source access
Original Russian full text, cohort selection and treatment descriptions checked. The 2006 Simashkova dissertation is a related archival source.
Source reviewed 2026-11-10.
Citation and original source
Original source: N. V. Simashkova, L. P. Yakupova. Cortexin in a longitudinal study of severe atypical autism Autism and Developmental Disorders. 2008;6(1):1–22. 2008.
Molekul research summary: https://molekul.io/research/cortexin-simashkova-yakupova-autism-2008. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry